review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Shawna Nesbitt | |
Addison A Taylor | |||
Helmy Siragy | |||
P2860 | cites work | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | Q28188182 | ||
Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research | Q28272171 | ||
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial | Q28286410 | ||
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers | Q33276389 | ||
Antiplatelet effect of losartan and telmisartan in patients with ischemic stroke | Q33298463 | ||
Redox signaling, vascular function, and hypertension | Q33689229 | ||
Newly emerging pharmacologic differences in angiotensin II receptor blockers | Q33839710 | ||
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity | Q33976477 | ||
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A | Q33989952 | ||
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | Q34327991 | ||
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study | Q34494252 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension | Q46511453 | ||
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy | Q46581957 | ||
The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Aten | Q46606291 | ||
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy | Q46616440 | ||
Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? | Q46656510 | ||
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients | Q46755592 | ||
Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg | Q56419300 | ||
Feasibility of treating prehypertension with an angiotensin-receptor blocker | Q34502178 | ||
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 | ||
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis | Q34604680 | ||
Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? | Q34943367 | ||
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension | Q35219694 | ||
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system | Q35991206 | ||
Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence | Q36210252 | ||
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials | Q36247551 | ||
The pleiotropic effects of angiotensin receptor blockers | Q36440956 | ||
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. | Q36745694 | ||
Vascular cognitive impairment: current concepts and clinical developments | Q37085101 | ||
Left ventricular hypertrophy and clinical outcomes in hypertensive patients | Q37147735 | ||
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial | Q37197711 | ||
Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis | Q37340888 | ||
Oxidative stress and hypertension | Q37475559 | ||
Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? | Q37513040 | ||
The current state of RAAS blockade in the treatment of hypertension and proteinuria | Q37623107 | ||
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan | Q37661553 | ||
Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering | Q37738157 | ||
Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy | Q37826797 | ||
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study | Q38371522 | ||
Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension | Q38497893 | ||
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women | Q40608305 | ||
Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension | Q40842306 | ||
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering | Q42165612 | ||
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 | ||
Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients | Q42630158 | ||
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study | Q43197135 | ||
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. | Q43573754 | ||
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension | Q43757678 | ||
A role for uric acid in the progression of renal disease | Q44223958 | ||
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial | Q44417511 | ||
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study | Q44529174 | ||
Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients | Q44624009 | ||
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy | Q44701637 | ||
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial | Q44979740 | ||
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study | Q45176683 | ||
Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. | Q45968750 | ||
Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. | Q45995805 | ||
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 | ||
P433 | issue | 9 | |
P921 | main subject | pharmacology | Q128406 |
P304 | page(s) | 677-686 | |
P577 | publication date | 2011-07-27 | |
P1433 | published in | Journal of Clinical Hypertension | Q15764150 |
P1476 | title | Angiotensin receptor blockers: pharmacology, efficacy, and safety | |
P478 | volume | 13 |